On Friday, Baird reaffirmed its Outperform ranking on shares of Longboard Prescription drugs Inc (NASDAQ:LBPH) with a worth goal of $60.00. The agency expressed a optimistic outlook on the corporate following current conferences with Longboard’s administration. The discussions bolstered Baird’s opinion that Longboard Prescription drugs is considerably undervalued compared to different firms in its sector.
The analyst at Baird highlighted the anticipation for Longboard’s upcoming investor and analyst occasion scheduled for September 16. This occasion is predicted to offer additional info on Longboard’s world part 3 program. This system’s focus is on bexicaserin, a remedy for seizures related to Developmental and Epileptic Encephalopathies (DEEs), meant to be used in people aged two years and older.
Bexicaserin is poised to enter a pivotal stage with the worldwide part 3 program, which might probably handle the wants of sufferers affected by DEEs, a bunch of situations which might be usually proof against remedy and have a major impression on high quality of life.
As of now, Longboard Prescription drugs is getting ready to share extra particulars about its plans and the progress of its medical program. The investor and analyst neighborhood is awaiting the September 16 occasion to achieve insights into the potential impression of bexicaserin on Longboard’s progress and its place within the pharmaceutical trade.
The reiterated worth goal and ranking mirror Baird’s confidence in Longboard Prescription drugs’ prospects and its ongoing dedication to creating therapies for complicated neurological situations. The market might be watching intently for updates from the corporate’s occasion in mid-September.
In different current information, Longboard Prescription drugs has seen a sequence of optimistic developments. The corporate’s drug, bexicaserin, acquired Breakthrough Remedy designation from the FDA for treating seizures related to Developmental and Epileptic Encephalopathies (DEEs) in sufferers aged two years and older. This important regulatory improvement led Baird to boost its worth goal for Longboard from $36 to $60, whereas sustaining an Outperform ranking.
Citi additionally elevated its worth goal from $40 to $45, sustaining a Purchase ranking, following the FDA’s approval of a Part 3 research for bexicaserin. The research targets completely different affected person subsets, together with Dravet syndrome and Lennox-Gastaut syndrome. Additional, Longboard reported promising preliminary outcomes from the PACIFIC OLE research, indicating a discount in seizure frequency.
Different analysts, together with these from H.C. Wainwright & Co and Cantor Fitzgerald, additionally maintain a bullish stance, setting a worth goal of $60. This exhibits the boldness in Longboard’s progress prospects following the FDA’s recognition of bexicaserin’s potential in treating DEEs.
Longboard plans to provoke a Part 3 program by the top of 2024 and expects Part 1 knowledge for an additional therapeutic candidate, LP659, within the second quarter of 2024. These current developments spotlight Longboard’s potential to deal with important unmet wants in epilepsy remedy.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
